{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:40:55Z","timestamp":1787161255136,"version":"build-2736575974"},"reference-count":8,"publisher":"Universa BV","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>The authors report the first adolescent (to our knowledge) in Belgium to receive duplimumab for eosinophilic esophagitis (EoE) and eosinophilic duodenitis (EoD). EoE was diagnosed in 2020 in a 13-year-old boy by endoscopy with biopsies following complaints of abdominal pain. Several treatments (omeprazole, topical steroids, and elemental diet) have been tried without adequate and sustained success. In 2023, in addition to the diagnosis of EoE, a diagnosis of mucosal EoD with significant ulceration was established. In January 2023, the EMA approved the use of dupilumab for EoE in children above the age of 12. Weekly subcutaneous dupilumab 300mg was started in November 2023. After three months, a complete endoscopic and histologic normalization of the esophagus and duodenum was achieved. He reported no further clinical signs or adverse events to date.<\/jats:p>","DOI":"10.51821\/88.1.13767","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T06:57:55Z","timestamp":1751266675000},"page":"207","source":"Crossref","is-referenced-by-count":2,"title":["Dupilumab in an adolescent with eosinophilic esophagitis and eosinophilic duodenitis, a valuable treatment option"],"prefix":"10.51821","volume":"88","author":[{"given":"S","family":"Vande Velde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hoorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Van Biervliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27062","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"LUCENDO A., MOLINA-INFANTE J., ARIAS A., et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adolescents. United European Gastroenterol. J., 2017, 5(3):335-358.","DOI":"10.1177\/2050640616689525"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"LOI R., CEULEMANS M., WAUTERS L., VANUYTSEL T. An update on eosinophilic esophagitis. Acta Gastroenterol. Belg., 2023, 86(4) :533-542.","DOI":"10.51821\/86.4.12001"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"PAPADOPOULOU A., AMIL-DIAS J., AUTH MK., et al. Joint ESPGHAN\/ NASPGHAN guidelines on childhood Eosinophilic Gastrointestinal Disorders beyond Eosinophilic Esophagitis. J. Pediatr. Gastroenterol. Nutr., 2024, 78(1):122-152.","DOI":"10.1097\/MPG.0000000000003877"},{"key":"ref3","unstructured":"EUROPEAN MEDICINES AGENCY, 2023, Meeting highlights from the committee for medicinal products for human use (CHMP), 23-26 January 2023, <https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dupixent>."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"ROTHENBURG ME., DELLON ES., COLLINS MH., et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents witheosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. Lancet Gastroenterol. Hepatol., 2023, 8(11):990-1004.","DOI":"10.1016\/S2468-1253(23)00204-2"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"AMIL-DIAS J., OLIVA S., PAPADOPOULOU A., et al. Diagnosis and management of eosinophilic esophagitis in children: An update form the European society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). J. Pediatr. Gastroenterol. Nutr., 2024, 79(2):394-437.","DOI":"10.1002\/jpn3.12188"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"SIA T., BACCHUS L., TANAKA R., KHUDA R., MALLIK S., LEUNG J. Dupilumab can induce remission of eosinophilic gastritis and duodenitis: a retrospective case series. Clin. Transl. Gastroenterol., 2024, 15(1):e00646.","DOI":"10.14309\/ctg.0000000000000646"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"MORI F., RENZO S., BARNI S., et al. Dupilumab treatment of eosinophilic gastrointestinal disease in an adolescent. Pediatr. Allergy Immunol., 2023, 34(6):e13973.","DOI":"10.1111\/pai.13973"}],"container-title":["Acta Gastro Enterologica Belgica"],"original-title":[],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T06:57:57Z","timestamp":1751266677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ageb.be\/ageb-journal\/ageb-volume\/ageb-article\/2243\/Dupilumab%20in%20an%20adolescent%20with%20eosinophilic%20esophagitis%20and%20eosinophilicduodenitis,%20a%20valuable%20treatment%20option\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":8,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,27]]}},"URL":"https:\/\/doi.org\/10.51821\/88.1.13767","relation":{},"ISSN":["1784-3227","1784-3227"],"issn-type":[{"value":"1784-3227","type":"print"},{"value":"1784-3227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}